The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Dec 16

PMID 39679910

Authors

Shigehiro Koganemaru

Shohei Koyama

Fumitaka Suto

Makito Koga

Koichiro Inaki

Yusuke Kuwahara

Takeo Arita

Tsuyoshi Hirata

Hiroki Goto

Naoya Wada

Maki Kobayashi

Tomoko Shibutani

Tatsuya Okabayashi

Kenji Nakamaru

Akihito Kawazoe

Yousuke Togashi

Yosuke Togashi

Hiroyoshi Nishikawa

Kohei Shitara

Affiliations

Soon will be listed here.

Abstract

This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.

References

Nishikawa H, Koyama S . Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021; 9(7). PMC: 8327843. DOI: 10.1136/jitc-2021-002591. View

Karasarides M, Cogdill A, Robbins P, Bowden M, Burton E, Butterfield L . Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunol Res. 2022; 10(4):372-383. PMC: 9381103. DOI: 10.1158/2326-6066.CIR-20-0586. View

Lu J, Xu Y, Wu Y, Huang X, Xie J, Wang J . Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer. BMC Cancer. 2019; 19(1):920. PMC: 6744628. DOI: 10.1186/s12885-019-6089-z. View

Kim R, An M, Lee H, Mehta A, Heo Y, Kim K . Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Cancer Discov. 2021; 12(4):984-1001. PMC: 9387589. DOI: 10.1158/2159-8290.CD-21-0888. View

Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T . An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity. 2020; 53(1):187-203.e8. DOI: 10.1016/j.immuni.2020.06.016. View

Seo S, Ryu M, Park Y, Ahn J, Park Y, Park S . Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2018; 22(3):527-535. DOI: 10.1007/s10120-018-0891-1. View

Ni Z, Xing D, Zhang T, Ding N, Xiang D, Zhao Z . Tumor-infiltrating B cell is associated with the control of progression of gastric cancer. Immunol Res. 2020; 69(1):43-52. DOI: 10.1007/s12026-020-09167-z. View

Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y . Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020; 38(17):1919-1927. DOI: 10.1200/JCO.19.03077. View

Totoki Y, Saito-Adachi M, Shiraishi Y, Komura D, Nakamura H, Suzuki A . Multiancestry genomic and transcriptomic analysis of gastric cancer. Nat Genet. 2023; 55(4):581-594. DOI: 10.1038/s41588-023-01333-x. View

10.

Bruni D, Angell H, Galon J . The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020; 20(11):662-680. DOI: 10.1038/s41568-020-0285-7. View

11.

Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S . Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019; 20(6):827-836. DOI: 10.1016/S1470-2045(19)30088-9. View

12.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

13.

Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H . The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov Oncol. 2022; 13(1):27. PMC: 9018954. DOI: 10.1007/s12672-022-00482-5. View

14.

Iwata T, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T . A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther. 2018; 17(7):1494-1503. DOI: 10.1158/1535-7163.MCT-17-0749. View

15.

Liu H, Wu J, Xu X, Wang H, Zhang C, Yin S . Peritumoral TIGITCD20 B cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer. Int Immunopharmacol. 2022; 108:108735. DOI: 10.1016/j.intimp.2022.108735. View

16.

Lim S, Wei J, Nguyen T, Shi H, Su W, Palacios G . Lipid signalling enforces functional specialization of T cells in tumours. Nature. 2021; 591(7849):306-311. PMC: 8168716. DOI: 10.1038/s41586-021-03235-6. View

17.

Fukai S, Nakajima S, Saito M, Saito K, Kase K, Nakano H . Down-regulation of stimulator of interferon genes (STING) expression and CD8 T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer. Gastric Cancer. 2023; 26(6):878-890. DOI: 10.1007/s10120-023-01417-x. View

18.

Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y . Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29(8):2110-2120. PMC: 10427426. DOI: 10.1038/s41591-023-02478-2. View

19.

Shitara K, Yamaguchi K, Muro K, Yasui H, Sakai D, Oshima T . Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study. Int J Clin Oncol. 2023; 29(1):27-35. PMC: 10764408. DOI: 10.1007/s10147-023-02422-x. View

20.

Fujiwara Y, Mittra A, Naqash A, Takebe N . A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. Cancer Drug Resist. 2022; 3(3):252-275. PMC: 8992481. DOI: 10.20517/cdr.2020.11. View